Châtillon, France, July 16, 2026
DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update
Continued productive engagement with the FDA in support of the BLA for the VIASKIN® Peanut Patch in children aged 4 through 7 years, with submission of the BLA anticipated in the third quarter of 2026
Reported cash and cash equivalents of $174.9 million as of June 30, 2026, funding into third quarter of 2027
DBV will host a conference call today, July 16, at 5:00pm ET
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a late-stage biopharmaceutical company, today reported financial results for the Second Quarter and Half-Year of 2026. The quarterly and Half-Year financial statements were approved by the Board of Directors on July 16, 2026.
"2026 is an important year for DBV as we continue to prepare to become a commercial company, if approved. I'm happy to report that we have made meaningful progress towards that goal in the first half of the year," said Daniel Tassé, Chief Executive Officer of DBV Technologies. "Recently, we shared the regulatory progress we've made through collaborative engagement with the FDA. We have also made judicious investments in launch readiness, while we continue to execute clinical studies that we expect will add further understanding to the potentially transformative value of the VIASKIN® Peanut Patch."
Half-Year 2026 Operational Highlights
Regulatory and Clinical Execution
Continued advancing the BLA submission for the VIASKIN® Peanut Patch in children aged 4 through 7 years.
Engaged in detailed and iterative discussions with the U.S. Food and Drug Administration (FDA) to support a complete, efficient and timely review of the BLA, once submitted. The FDA has not requested additional data.
DBV is incorporating valuable, actionable feedback from the FDA specific to the organization, mapping and formatting of existing CMC and biostatistical data sets, and now anticipates submitting the BLA in the third quarter of 2026.
Recruitment was closed in the second quarter of 2026 for the COMFORT Toddlers supplemental safety study, an important operational milestone in the continued advancement of the VIASKIN® Peanut Patch in toddlers aged 1 through 3 years.
Initiated the THRIVE study evaluating the efficacy and safety of the VIASKIN® Peanut Patch in achieving ad lib consumption of dietary peanut in infants aged 6 through 12 months with peanut allergy after 3-4 years of treatment with the VIASKIN® Peanut Patch.